Bristol Myers Squibb (BMS) has presented new data from its phase 3 POETYK PsA-1 trial, showing that Sotyktu (deucravacitinib) significantly improved symptoms in adults with active psoriatic arthritis (PsA) compared to placebo. Findings were shared at the 2025 European Alliance of Associations for Rheumatology (EULAR) Congress in Barcelona, Spain, taking place 11 to 14 June. […]
The post Bristol Myers Squibb reports positive results for psoriatic arthritis treatment appeared first on Pharmafile.
